Webb10 juni 2024 · Androgen deprivation therapy (ADT) is beneficial for unfavorable intermediate-risk (IR) prostate cancer patients receiving curative radiotherapy (RT). … Webb7 apr. 2024 · This resistance was presumed to be due to sustained AR signaling via non-prostate sources of androgens. 2 Once the patient develops CRPC, additional AR inhibiting therapies are administered with decreasing effectiveness as more lines of therapy are given. 3, 4 In addition to therapeutic resistance, chronic exposure to ADT leads to excess …
New Protocol of Intermittent Androgen Deprivation Therapy for
Webb21 feb. 2024 · 111. Background: Advancement of treatment pathways in the management of metastatic prostate cancer (mPC) has identified newer systemic agents associated with survival advantage over androgen deprivation therapy (ADT) alone. Despite FDA approvals and guideline recommendations outlining standard of care (SOC) intensification of … Webb17 jan. 2024 · Randomised trials have investigated various androgen deprivation therapy (ADT) intensification strategies in men receiving radiotherapy for the treatment of … psa essentials sale
Bone health effects of androgen-deprivation therapy and androgen …
WebbBackground: The optimal points for halting and resuming treatment in intermittent androgen deprivation therapy (IADT) for metastatic prostate cancer patients are … Webb6 aug. 2024 · JCOG0401 investigated whether salvage radiotherapy to the prostate bed (64.8 Gy) followed by salvage ADT (80 mg bicalutamide daily), in the case of salvage radiotherapy failure, was superior to ... Webb7 okt. 2024 · In patients with prostate cancer, three main drivers of fragility fracture risk are: (1) the aging process, (2) cancer treatment, primarily with ADT, and (3) cancer phenotype. psa eolys